The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 01, 2025

Filed:

Dec. 19, 2022
Applicant:

Crispr Therapeutics Ag, Zug, CH;

Inventors:

Valentin Sluch, South Boston, MA (US);

Alireza Rezania, South Boston, MA (US);

Jason Sagert, South Boston, MA (US);

Danielle Swain, South Boston, MA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/85 (2006.01); A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); C07K 14/54 (2006.01); C07K 14/715 (2006.01); C07K 14/725 (2006.01); C07K 14/74 (2006.01); C07K 14/81 (2006.01); C07K 16/28 (2006.01); C12N 5/0735 (2010.01); C12N 5/074 (2010.01); C12N 5/0783 (2010.01); C12N 5/10 (2006.01); C12N 15/66 (2006.01); C12N 15/90 (2006.01);
U.S. Cl.
CPC ...
C07K 14/70539 (2013.01); A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/4215 (2025.01); C07K 14/5443 (2013.01); C07K 14/7051 (2013.01); C07K 14/7155 (2013.01); C07K 14/8121 (2013.01); C07K 16/2878 (2013.01); C12N 5/0606 (2013.01); C12N 5/0646 (2013.01); C12N 5/0696 (2013.01); C12N 5/10 (2013.01); C12N 15/66 (2013.01); C12N 15/85 (2013.01); C12N 15/907 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); C07K 2319/00 (2013.01); C12N 2310/20 (2017.05); C12N 2506/11 (2013.01); C12N 2510/00 (2013.01);
Abstract

The present invention relates to, inter alia, an engineered cell (e.g., iPSC, IPS-derived NK, or NK cell) comprising a disrupted B2M gene and an inserted polynucleotide encoding one or more of SERPINB9, a fusion of IL15 and IL15Rα, and/or HLA-E. The engineered cell can further comprise a disrupted CIITA gene and an inserted polynucleotide encoding a CAR, wherein the CAR can be an anti-BCMA CAR or an anti-CD30 CAR. The engineered cell may further comprise a disrupted ADAM17 gene, a disrupted FAS gene, a disrupted CISH gene, and/or a disrupted REGNASE-1 gene. Methods for producing the engineered cells are also provided, and therapeutic uses of the engineered cells are also described. Guide RNA sequences targeting described target sequences are also described.


Find Patent Forward Citations

Loading…